secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-10-16T13:29:32+00:00
Accession:  0001437749-26-032762
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Moleculin Biotech furnishes Oct 16, 2026 investor presentation under Reg FD; exhibit text not included
--------------------------------------------------------------------------------

- Moleculin Biotech (MBRX) disclosed a corporate investor presentation dated October 16, 2026 as Exhibit 99.1 under Item 7.01 Regulation FD.
- Filing states the presentation is posted on the Company's website, but the exhibit supplied contains no readable content beyond the 'Exhibit 99.1' header.
- No financial results, clinical trial data, guidance, or transaction terms appear anywhere in the filing body; no specific facts can be extracted.
- Signed by Jonathan P. Foster on October 16, 2026; company address listed as 5300 Memorial Drive, Suite 950, Houston, TX 77007.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926032762/0001437749-26-032762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926032762/mbrx20261015_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer